Table 1.
Results of trials in patients with metastatic cholangiocarcinoma
| Study/result | Objective response rate, % | Progressionfree survival, months | Overall survival, months |
|---|---|---|---|
| MET inhibition | |||
| Phase 2 study, cabozantinib [12] FGFR inhibition | 0 | 1.8 | 5.2 |
| Phase 2 study (FIGHT-202), pemigatinib [19] | 35.5 | 6.9 | 21.1 |
| Phase 2 study, infigratinib [21] IDH1 inhibition | 26.9 | 6.8 | 12.5 |
| Phase 3 study (ClarIDHy), ivosidenib [25, 26] | 2 | 2.7 | 10.3 |
| Phase 1 study, ivosidenib [27] Immune checkpoint inhibitors | 5 | 3.8 | − |
| Phase 1 study, nivolumab with gemcitabine and cisplatin1 [30] | 37 | 4.2 | 15.4 |
| Phase 2 study, nivolumab [31] | 22 | 3.68 | 14.24 |
| Phase 1b study (KEYNOTE 028), pembrolizumab [32] | 13 | 1.8 | 6.2 |
| Phase 2 study (KEYNOTE 158), pembrolizumab [32] Phase 1 study [33] | 5.8 | 2 | 7.4 |
| Durvalumab alone | 4.8 | − | 8.1 |
| Durvalumab/tremelimumab | 11 | 10.1 | |
| Phase 2 randomized study [34] Atezolizumab alone | 32.3 | 1.87 | Not mature |
| Atezolizumab/cobimetinib | 45.1 | 3.65 |
FGFR, fibroblast growth factor receptor; IDH, isocitrate dehydrogenase.
1
This combination was studied in treatment-naive patients.